Carter Bankshares Supports eMed's Innovative Weight Management Approach with Wegovy® Recognition

eMed Population Health Pioneers New Approach to Weight Management with Wegovy® Recognition

eMed Population Health gains significant recognition as a Novocare® Recognized Care Provider by Novo Nordisk for its innovative delivery of Wegovy® (oral semaglutide), the first oral GLP-1 medication approved by the FDA for chronic weight management in adults. This acknowledgment comes on the heels of Wegovy®'s FDA approval in December 2025, positioning eMed at the forefront of a transformative approach to weight loss. By offering a once-daily, non-injectable option, eMed aims to address the growing obesity epidemic with a focus on structured care and personalized support.

The effectiveness of eMed's approach lies in its commitment to clinically guided practices that emphasize accountability and ongoing patient engagement. Linda Yaccarino, eMed’s CEO, states that the organization seeks to reshape the delivery of GLP-1 medications by integrating a comprehensive support system that ensures consistent results for patients managing their weight. This approach responds to the prevalent issue of unpredictable outcomes in weight management, which often leads to frustration among patients. By fostering continuous interaction and tailored guidance, eMed enhances the likelihood of adherence to treatment regimens, which is crucial for achieving sustainable weight loss.

Clinical studies underline the efficacy of the Wegovy® regimen, revealing a notable average weight loss of approximately 17% among patients who adhere to the program alongside a reduced-calorie diet and exercise. eMed’s structured care model aims to simplify weight management by embedding the treatment into patients' daily lives, reinforcing the necessity of sustained engagement with their care programs. By doing so, eMed not only promotes the successful integration of Wegovy® into patients' routines but also underscores the critical role of ongoing medical support in achieving long-term health outcomes.

In related news, the Ohio Health Care Association (OHCA) appoints Scott D. Wiley, CAE, as its new chief executive officer, effective January 2026. Wiley brings over 20 years of strategic leadership experience, having previously driven significant change at CoreNet Global and the Ohio Society of CPAs (OSCPA). His expertise in policy and coalition-building is expected to enhance member engagement and innovation for OHCA during a pivotal time in the healthcare landscape.

Wiley’s leadership is anticipated to strengthen OHCA's mission, providing essential support to its members as they navigate the complexities of the evolving health care environment in Ohio. His history of collaborative efforts with governmental and industry stakeholders positions him as a key figure in driving positive change and enhancing the stability of health services across the state.